Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
OncoCyte Corporation (OCX) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OncoCyte Corporation (OCX) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for May 6th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 6th:
MAIA Biotechnology, Inc. (MAIA - Free Report) : This immuno-oncology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 44.4% over the last 60 days.
MAIA Biotechnology, Inc. Price and Consensus
MAIA Biotechnology, Inc. price-consensus-chart | MAIA Biotechnology, Inc. Quote
MAIA’s shares gained 0.5% over the last three months compared with the S&P 500’s decline of 5.6%. The company possesses a Momentum Score of A.
MAIA Biotechnology, Inc. Price
MAIA Biotechnology, Inc. price | MAIA Biotechnology, Inc. Quote
Byrna Technologies Inc. (BYRN - Free Report) : This non-lethal defense technology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 25% overthe last 60 days.
Byrna Technologies Inc. Price and Consensus
Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote
Byrna’s shares gained 33.8% over the last six months compared with the S&P 500’s decline of 4.7%. The company possesses a Momentum Score of B.
Byrna Technologies Inc. Price
Byrna Technologies Inc. price | Byrna Technologies Inc. Quote
OncoCyte Corporation (OCX - Free Report) : This precision diagnostics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 39.3% over the last 60 days.
OncoCyte Corporation Price and Consensus
OncoCyte Corporation price-consensus-chart | OncoCyte Corporation Quote
OncoCyte’s shares gained 45.3% over the last three months compared with the S&P 500’s decline of 5.6%. The company possesses a Momentum Score of B.
OncoCyte Corporation Price
OncoCyte Corporation price | OncoCyte Corporation Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.